Potential alteration of tumor microenvironments by β-mercaptoethanol

Area of Science:

• Immunology
• Oncology
• Biochemistry

Background:

• Immune checkpoint inhibitors (ICIs) show profound therapeutic effects in cancer but face limitations due to adverse events and low cure rates.
• The tumor microenvironment (TME) significantly impacts ICI efficacy.
• Low-molecular-weight thiols are known to modulate immune processes and may offer a strategy to enhance ICI therapy by targeting the TME.

Purpose of the Study:

• To explore the potential of beta-mercaptoethanol (BME), a potent low-molecular-weight thiol, to improve cancer patient survival rates when used with ICIs.
• To investigate BME's effects on immune cell proliferation/differentiation, lymphocyte exhaustion, tumor antigen immunogenicity, and suppressor cell/factor inactivation within the TME.

Main Methods:

• Literature review on low-molecular-weight thiols and their immune-modulating properties.
• Proposed clinical assessment of BME's therapeutic benefits in cancer patients undergoing ICI therapy.
• Focus on BME's potential mechanisms: glutathione maintenance in lymphocytes, suppressor cell inhibition, and reactive oxygen species (ROS) inactivation.

Main Results:

• The study hypothesizes that BME can enhance ICI effectiveness through specific TME alterations.
• Projected effective BME alterations include facilitating cysteine uptake for glutathione replacement in lymphocytes.
• Inhibition of suppressor cells/factors and inactivation of ROS are also identified as key beneficial mechanisms.

Conclusions:

• BME holds potential as an adjunct therapy to improve outcomes for cancer patients treated with ICIs.
• Further clinical investigation is warranted to validate BME's efficacy in modulating the TME and enhancing anti-tumor immunity.
• Targeting the TME with specific thiols like BME could overcome current limitations in cancer immunotherapy.